HBK Investments’s Cidara Therapeutics CDTX Stock Holding History

HBK Investments’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,260,000	Closed	-$278M	–	353
2025 Q4	$278M	Buy	+1,260,000	New	+$204M	2.19%	17

HBK Investments's CDTX Position: Q1 2026 in Review

HBK Investments sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 1,260,000 shares — an estimated $278M sold.

HBK Investments first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $278M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

HBK Investments reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
HBK Investments sold 1,260,000 Cidara Therapeutics shares in Q1 2026, an estimated $278M.
HBK Investments first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
HBK Investments's Cidara Therapeutics position peaked at $278M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on HBK Investments's 13F filing for Q1 2026, filed 15 May 2026.